Drug Approval | April 10, 2023
Virpax reports on progress of Envelta
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
The milestone of operating continuously a very complex system for over two years has demonstrated the effectiveness of integrated laboratory automation solutions
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Government hospitals like AIIMS, KGMC & many more as per day OPD patients are 18-25 thousand
Successes under Ayushman Bharat Digital Health Mission and Pradhan Mantri National Dialysis Programme highlighted
The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.
Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
Subscribe To Our Newsletter & Stay Updated
